$4.23
+0.27 (+6.82%)
Open$3.98
Previous Close$3.96
Day High$4.28
Day Low$3.97
52W High$1,299.60
52W Low—
Volume—
Avg Volume32.2K
Market Cap4.50M
P/E Ratio—
EPS$-18,826.52
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+567.8% upside
Current
$4.23
$4.23
Target
$28.25
$28.25
$22.50
$28.25 avg
$48.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |
| Rev Growth | -6.5% | +19.5% | +20.8% |
| Debt/Equity | 0.95 | 1.14 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |